Beyond first-line systemic treatment for metastatic urothelial carcinoma of the bladder.
Clin Transl Oncol
; 21(3): 280-288, 2019 Mar.
Article
in En
| MEDLINE
| ID: mdl-30182210
ABSTRACT
Metastatic urothelial carcinoma of the bladder is a rarely curable disease. Patients receive systemic therapy with limited response rates and survival benefits. The rescue regimens of these patients who have failed first-line treatment had remained problematic until the recent advances. Several trials with novel regimens, including immune checkpoint inhibitors and targeted therapy, to salvage relapsed urothelial carcinoma of the bladder have recently been published. However, the choice of an optimal treatment regimen remains challenging in the absence of randomized trials comparing regimen sequences. Daily clinical cases provoke the question of whether there is a preferred second-line regimen. This paper provides an overview of recent trials and proposes a management algorithm based on subgroup analyses and prognostic features.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Algorithms
/
Carcinoma, Transitional Cell
/
Salvage Therapy
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Clin Transl Oncol
Year:
2019
Document type:
Article
Affiliation country:
Líbano